HIV Scientific Papers

Effect of tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analogue, on visceral adipose tissue (VAT) in HIV-infected patients with excess abdominal fat: impact of antiretroviral therapy regimen.
2008
Falutz J, Mamputu J-C, Marsolais C, et al.
"Poster #P19 presented at: 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; November 6-8, 2008; London, UK. "
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
2008
AIDS.
Falutz J, Allas S, Mamputu J-C, et al.
2(14):1719-1728.
Learn more
Long-term effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, on lipid and glucose parameters in HIV-infected patients with abdominal fat accumulation [abstract].
2008
Falutz J, Allas S, Mamputu J-C, et al.
ENDO 2008; June 15-18, 2008; San Francisco, California, USA.
Data on 52-week safety and efficacy of tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analogue, in HIV-infected patients with abdominal fat accumulation.
2008
Falutz J, Allas S, Mamputu J-C, et al.
Poster #943 presented at: Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts, USA.
Long-term safety and efficacy of tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analogue, in HIV-infected patients with abdominal fat accumulation [abstract].
2007
Falutz J, Allas S, Mamputu J-C, et al.
Presented at: 11th European AIDS conference (EACS); October 24-27 2007; Madrid, Spain.